Announced Fri, 14 Aug · 21:04 IST
Nectar Lifesciences posts Q1 FY27 loss of Rs 13.46 cr, appoints director
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹11.10
prior close
₹11.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.5+4.5+4.5+3.4-2.7-4.8-7.2-4.5-2.7+12.3+9.3-0.9——
Up moveDown movePending
AI summary
Nectar Lifesciences posted Q1 FY27 standalone loss of Rs 13.46 cr from continuing operations, versus Rs 37.21 cr loss in Q4 FY26. Total income from continuing operations was Rs 6.29 cr. Company booked a Rs 25.13 cr loss from mutual fund and equity investments hit by market volatility. Board appointed Dr. Gunmala Suri as Non-Executive Non-Independent Director from Aug 15, 2026. 31st AGM scheduled for Sep 18.
Likely market impact
Sustained losses and Rs 25.13 cr investment write-down weigh on sentiment. Director appointment and AGM are routine. Real estate pivot underway.